Teva Pharmaceutical (TEVA) Stock Plunges 18% But Saves $43 Billion Across Major Markets: Promising Stock Worth Your Money.
Since June 24, when Teva’s stock was at $10.42, it was on a constant decline. Today, after more than a month, it is currently at $8.8 in the pre-market. The company today published astonishing reports. Teva saved the United States $28.8 billion in 2020, $4.2 billion of which were direct savings to US patients. Teva brought $9.6 billion in savings in 2020 to healthcare systems across nine European countries, including the UK, Germany, and Spain.
Teva’s Economic Impact Report, an independent study by Matrix Global Advisors (MGA), showed how Teva, the leading provider of generic medicines, saved $43.1 billion across its major markets in 2020 alone.
Amid the COVID-19 pandemic, Teva’s manufacturing, distribution, and R&D sites remained open to supply quality, affordable medicines to nearly 200 million patients every day. In addition, the company’s economic activity supported nearly 250,000 work spots and added $52 billion to economic results across 15 countries.
No comments:
Post a Comment